ES2197421T3
(es)
*
|
1992-04-02 |
2004-01-01 |
Smithkline Beecham Corporation |
Compuestos utiles para tratar enfermedades alergicas e inflamatorias.
|
ATE275951T1
(de)
*
|
1993-06-18 |
2004-10-15 |
Smithkline Beecham Corp |
Verfahren zur identifizierung eines pde iv hemmers
|
EP0722322B1
(en)
*
|
1993-10-01 |
2001-11-14 |
Smithkline Beecham Corporation |
Compounds, compositions and treatment of allergies and inflammation therewith
|
GB9404706D0
(en)
*
|
1994-03-11 |
1994-04-27 |
Smithkline Beecham Corp |
Compounds
|
US6013827A
(en)
*
|
1994-03-11 |
2000-01-11 |
Smithkline Beecham Corporation |
Compounds
|
US5998428A
(en)
*
|
1995-05-31 |
1999-12-07 |
Smithkline Beecham Corporation |
Compounds and methods for treating PDE IV-related diseases
|
JPH10511389A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
4,4−(二置換)シクロヘキサン−1−オール二量体および関連化合物
|
US5777160A
(en)
*
|
1994-12-23 |
1998-07-07 |
Smithkline Beecham Corporation |
1, 4, 4-(trisubstituted) cyclohex-1-ene dimers and related compounds
|
ZA9510826B
(en)
*
|
1994-12-23 |
1996-06-20 |
Smithkline Beecham Corp |
3,3-(disubstituted)cyclohexan-1-ol monomers and related compounds
|
JPH10511391A
(ja)
*
|
1994-12-23 |
1998-11-04 |
スミスクライン・ビーチャム・コーポレイション |
3,3−(二置換)シクロヘキサン−1−オール二量体および関連化合物
|
CZ196097A3
(cs)
*
|
1994-12-23 |
1998-01-14 |
Smithkline Beecham Corporation |
4,4-(Disubstituované)cyklohexan-1-olové monomery a odvozené sloučeniny, farmaceutický prostředek a použití
|
EP0799204A4
(en)
*
|
1994-12-23 |
1998-03-25 |
Smithkline Beecham Corp |
MONOMERS OF 1,3,3- (TRISUBSTITUE) CYCLOHEXANE AND RELATED COMPOUNDS
|
AU698028B2
(en)
*
|
1995-05-18 |
1998-10-22 |
Altana Pharma Ag |
Phenyldihydrobenzofurans
|
US6080782A
(en)
*
|
1995-05-18 |
2000-06-27 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Cyclohexyl dihydrobenzofuranes
|
AR004471A1
(es)
*
|
1995-05-31 |
1998-12-16 |
Smithkline Beecham Corp |
Compuestos de ciclohexan-1-ol-4,4-disustituidos, utiles en el tratamiento de enfermedades alergicas e inflamatorias y composiciones farmaceuticas que lascontienen
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US5891883A
(en)
*
|
1995-12-21 |
1999-04-06 |
Smithkline Beecham Corporation |
4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6288261B1
(en)
|
1998-12-18 |
2001-09-11 |
Abbott Laboratories |
Inhibitors of matrix metalloproteinases
|
DZ3019A1
(fr)
*
|
1999-03-01 |
2005-05-20 |
Smithkline Beecham Corp |
Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
|
US20020077276A1
(en)
*
|
1999-04-27 |
2002-06-20 |
Fredeking Terry M. |
Compositions and methods for treating hemorrhagic virus infections and other disorders
|
ECSP003599A
(es)
*
|
1999-08-06 |
2002-03-25 |
Smithkline Beecham Corp |
Procedimiento para preparar acidos a traves de alfa-coroepoxi-esteres
|
US20040220424A1
(en)
*
|
1999-08-06 |
2004-11-04 |
Smithkline Beecham Corporation |
Process for preparing acids via alpha-chloroepoxy esters
|
ES2260043T3
(es)
|
1999-08-21 |
2006-11-01 |
Altana Pharma Ag |
Combinacion sinergica de roflumilast y salmeterol.
|
US6572794B1
(en)
|
2000-07-24 |
2003-06-03 |
Essilor International Compagnie Generale D'optique |
Method of manufacturing a photochromic molded article
|
FR2816950B1
(fr)
|
2000-11-17 |
2003-02-14 |
Essilor Int |
Procede d'obtention d'un latex photochromique
|
FR2819258B1
(fr)
|
2001-01-11 |
2003-04-11 |
Essilor Int |
Procede d'obtention d'un latex photochromique stabilise, latex obtenu et application a l'optique ophtalmique
|
CA2817619A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
TWI354561B
(en)
|
2002-07-19 |
2011-12-21 |
Abbott Lab S A |
Pharmaceutical compositions and uses for treatment
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US7153824B2
(en)
|
2003-04-01 |
2006-12-26 |
Applied Research Systems Ars Holding N.V. |
Inhibitors of phosphodiesterases in infertility
|
US20050026883A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050085430A1
(en)
*
|
2003-07-31 |
2005-04-21 |
Robinson Cynthia B. |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20090274676A1
(en)
*
|
2003-07-31 |
2009-11-05 |
Robinson Cynthia B |
Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
|
US20050187278A1
(en)
*
|
2003-08-28 |
2005-08-25 |
Pharmacia Corporation |
Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
|
EP1679069A4
(en)
*
|
2003-10-21 |
2009-05-13 |
Dainippon Sumitomo Pharma Co |
NEW PIPERIDINE DERIVATIVE
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
NZ627177A
(en)
|
2005-05-16 |
2016-02-26 |
Abbvie Biotechnology Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
US20070041905A1
(en)
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
EP2532677A1
(en)
|
2005-10-21 |
2012-12-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
CA2626804A1
(en)
|
2005-11-01 |
2007-08-09 |
Abbott Biotechnology Ltd. |
Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
|
GB0526244D0
(en)
|
2005-12-22 |
2006-02-01 |
Novartis Ag |
Organic compounds
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
NZ596517A
(en)
|
2006-04-05 |
2013-06-28 |
Abbott Biotech Ltd |
Antibody purification
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
EP2708242A3
(en)
|
2006-04-10 |
2014-03-26 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of ankylosing spondylitis
|
CA2564435A1
(en)
|
2006-04-10 |
2007-10-10 |
Abbott Biotechnology Ltd. |
Methods for monitoring and treating intestinal disorders
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
NZ571429A
(en)
|
2006-04-21 |
2011-09-30 |
Novartis Ag |
Purine derivatives for use as adenosine A2A receptor agonists
|
CN103316403B
(zh)
|
2006-06-30 |
2017-05-24 |
艾伯维生物技术有限公司 |
自动注射装置
|
EP2081933B1
(en)
|
2006-09-29 |
2011-03-23 |
Novartis AG |
Pyrazolopyrimidines as pi3k lipid kinase inhibitors
|
RU2009120389A
(ru)
|
2006-10-30 |
2010-12-10 |
Новартис АГ (CH) |
Гетероциклические соединения в качестве противовоспалительных агентов
|
US20080176901A1
(en)
|
2007-01-10 |
2008-07-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
US20090182035A1
(en)
*
|
2007-04-11 |
2009-07-16 |
Alcon Research, Ltd. |
Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
|
KR20100014565A
(ko)
*
|
2007-04-11 |
2010-02-10 |
알콘 리서치, 리미티드 |
알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 tnfa의 억제제 및 항히스타민의 용도
|
DE602008005140D1
(de)
|
2007-05-07 |
2011-04-07 |
Novartis Ag |
Organische verbindungen
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
WO2008154543A2
(en)
|
2007-06-11 |
2008-12-18 |
Abbott Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis
|
ES2654395T3
(es)
|
2007-12-10 |
2018-02-13 |
Novartis Ag |
Análogos de amilorida espirocíclicos como bloqueantes de ENaC
|
PT2231642E
(pt)
|
2008-01-11 |
2014-03-12 |
Novartis Ag |
Pirimidinas como inibidores de quinase
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CN102112130A
(zh)
|
2008-06-10 |
2011-06-29 |
诺瓦提斯公司 |
作为上皮钠通道阻滞剂的吡嗪衍生物
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
JP5677411B2
(ja)
|
2009-04-29 |
2015-02-25 |
アッヴィ バイオテクノロジー リミテッド |
自動注入機器
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
EA026693B1
(ru)
|
2009-08-17 |
2017-05-31 |
Интелликайн ЭлЭлСи |
Производные бензоксазола и бензотиазола в качестве ингибиторов pi3-киназы
|
IN2012DN01453A
(GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
|
2009-08-20 |
2015-06-05 |
Novartis Ag |
|
AU2010300421B2
(en)
*
|
2009-10-01 |
2014-01-23 |
Alcon Research, Ltd. |
Olopatadine compositions and uses thereof
|
WO2011050325A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
JP2013514388A
(ja)
|
2009-12-16 |
2013-04-25 |
フィリップ ボッシュ, |
間質性膀胱炎の処置の方法
|
JP2013518590A
(ja)
|
2010-02-02 |
2013-05-23 |
アボツト・バイオテクノロジー・リミテツド |
TNF−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
ES2727275T3
(es)
|
2010-04-21 |
2019-10-15 |
Abbvie Biotechnology Ltd |
Dispositivo automático de inyección portátil para la liberación controlada de agentes terapéuticos
|
WO2011146727A1
(en)
|
2010-05-19 |
2011-11-24 |
Philip Bosch |
Methods of treating interstitial cystitis
|
MX2012014080A
(es)
|
2010-06-03 |
2013-05-01 |
Abbvie Biotechnology Ltd |
Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
WO2012103141A1
(en)
|
2011-01-24 |
2012-08-02 |
Abbott Biotechnology Ltd. |
Automatic injection devices having overmolded gripping surfaces
|
EP2673277A1
(en)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
US9127000B2
(en)
|
2011-02-23 |
2015-09-08 |
Intellikine, LLC. |
Heterocyclic compounds and uses thereof
|
BR112013021638A2
(pt)
|
2011-02-25 |
2016-08-02 |
Irm Llc |
"compostos inibidores de trk, seu uso e composições que os compreendem"
|
EP3366698A1
(en)
|
2011-03-01 |
2018-08-29 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase c agonists
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
UY34305A
(es)
|
2011-09-01 |
2013-04-30 |
Novartis Ag |
Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
|
EA026655B1
(ru)
|
2011-09-15 |
2017-05-31 |
Новартис Аг |
6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
EP2755652B1
(en)
|
2011-09-16 |
2021-06-02 |
Novartis AG |
N-substituted heterocyclyl carboxamides
|
WO2013078440A2
(en)
|
2011-11-23 |
2013-05-30 |
Intellikine, Llc |
Enhanced treatment regimens using mtor inhibitors
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
EP3964513A1
(en)
|
2012-04-03 |
2022-03-09 |
Novartis AG |
Combination products with tyrosine kinase inhibitors and their use
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
AU2014218599C1
(en)
|
2013-02-25 |
2018-09-06 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists for use in colonic cleansing
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
SG11201507230PA
(en)
|
2013-03-12 |
2015-10-29 |
Abbvie Inc |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
JP2016514670A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
EA201592263A1
(ru)
|
2013-06-05 |
2016-05-31 |
Синерджи Фармасьютикалз, Инк. |
Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
|
KR102456567B1
(ko)
|
2013-08-09 |
2022-10-19 |
알데릭스, 인코포레이티드 |
인산염 수송을 억제하기 위한 화합물 및 방법
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
US9862711B2
(en)
|
2014-04-24 |
2018-01-09 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
BR112016024533A8
(pt)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas
|
PL3134396T3
(pl)
|
2014-04-24 |
2020-04-30 |
Novartis Ag |
Pochodne aminopirydyny jako inhibitory 3-kinazy fosfatydyloinozytolu
|
WO2015198320A1
(en)
|
2014-06-24 |
2015-12-30 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
BR112017001695A2
(pt)
|
2014-07-31 |
2017-11-21 |
Novartis Ag |
terapia de combinação
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
WO2020048827A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Aktiengesellschaft |
1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
|
WO2020048828A1
(en)
|
2018-09-03 |
2020-03-12 |
Bayer Pharma Aktiengesellschaft |
5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds
|
EP3972599A1
(en)
|
2019-05-21 |
2022-03-30 |
Ardelyx, Inc. |
Combination for lowering serum phosphate in a patient
|
BR112021024668A2
(pt)
|
2019-06-10 |
2022-05-31 |
Novartis Ag |
Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
|
BR112022002569A2
(pt)
|
2019-08-28 |
2022-07-19 |
Novartis Ag |
Derivados de 1,3-fenil heteroarila substituídos e seu uso no tratamento de doenças
|
CN118829936A
(zh)
|
2022-04-26 |
2024-10-22 |
依视路国际公司 |
具有镜面涂层的光致变色光学制品
|